MedTrace Logo

Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes

NCT00655044 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3637

Last updated 2016-10-28

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655044 on ClinicalTrials.gov